Eli Lilly and Company (LLY)
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
The latest trading day saw Eli Lilly (LLY) settling at $916.31, representing a +1.47% change from its previous close.
LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?
LLY's obesity drugs fuel explosive growth, while ABBV depends on Skyrizi and Rinvoq. Let's see which drugmaker has the stronger 2026 outlook.
LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D
Eli Lilly reports strong Phase III results for retatrutide in type 2 diabetes, with significant A1C reduction and up to 16.8% weight loss in the latest study.
Eli Lilly's next-generation obesity drug retatrutide clears first late-stage diabetes trial
Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared to placebo, and helped patients lose an average of 16.8% of their weight.
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
Eli Lilly (LLY) concluded the recent trading session at $930.5, signifying a -5.93% move from its prior day's close.
Why One Analyst Thinks LLY Is Worth $850 While the Rest of Wall Street Targets $1,216
Eli Lilly ( NYSE:LLY ) shares have pulled back sharply, falling 9% over the past month, and 13% year-to-date.
Eli Lilly falls after a 6 month rally; is this a buy the dip opportunity?
Shares of Eli Lilly came under pressure on Tuesday after HSBC downgraded the stock, raising fresh questions about whether the pharmaceutical giant's strong run in the obesity drug market can continue or if investors should reassess valuations. The stock slipped 4.2% following the downgrade, even as it remains one of the best-performing large-cap healthcare names over the past year.
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Eli Lilly Warns Tirzepatide-B12 Mix in Compounded Drugs May Pose Safety Risks
Eli Lilly (LLY) has raised new safety concerns around compounded versions of its weight-loss medicine Zepbound, warning that the drug's active ingredient, tirze
Eli Lilly: The Weight-Loss Craze Isn't Over
Eli Lilly is rated a strong buy with a $1,623 price target, driven by multiple near- and long-term catalysts. Orforglipron's Q2 launch and Medicare/Medicaid eligibility will expand LLY's addressable market and offset anticipated price erosion. Retatrutide's potential 2027 approval offers another growth leg, with superior efficacy targeting the most severe obesity cases.
